Preclinical work suggests benzyl]-4-methoxybutyramide), a novel metabotropic glutamate receptor subtype 5 negative allosteric modulator, may represent a novel pharmacological treatment for alcohol use disorder. Two independent experiments evaluated the effect of acutely administered GET 73 (0, 30, and 100 mg/kg, intragastrically) on alcohol-induced hypolocomotion (n=72) and sedation/hypnosis (n=36) in rats. In healthy male volunteers (n=14), an open-label, randomised, crossover study was conducted to compare adverse events and pharmacokinetic parameters, in two experiments in which 300 mg GET 73 was administered, with and without alcohol, once and thrice. In rats, when administered with alcohol-vehicle, 100 mg/kg, but not 30 mg/kg, GET 73 reduced spontaneous locomotor activity. When administered with alcohol, no dose of GET 73 altered either alcohol-induced hypolocomotion or sedation/hypnosis. In humans, both single and thrice 300 mg GET 73 administration were well tolerated, in the presence and absence of alcohol, with no differences in adverse events. There were no significant differences in relative bioavailability between administering 300 mg GET 73 in the presence or absence of alcohol.
Introduction
Alcohol use disorder (AUD) represents a worldwide medical and social problem with few approved pharmacotherapies (HaassKoffler et al., 2014) . The neurotransmitter glutamate plays key roles in the neurobiological mechanisms that lead to alcohol craving and excessive drinking (Gilpin and Koob, 2008) .
Glutamate activates both metabotropic glutamate receptors (mGluRs), which are G-protein coupled receptors that mediate slow glutamate transmission, and ionotropic glutamate receptors (iGluRs) that mediate fast excitatory glutamate transmission. Blockade of glutamate transmission via both iGluRs/mGluRs reduces the rewarding effects of alcohol (D 'Souza, 2015; Duncan and Lawrence, 2012) . When tested in humans, iGluR antagonists may exhibit serious side effects (Olive, 2009) . By contrast, mGluR ligands have a safer profile when tested in clinical trials for various medical conditions (Spooren et al., 2003; Witkin et al., 2007) . In addition, preclinical work suggests that mGluRs represent a valid target for developing new pharmacotherapies for AUD (Duncan and Lawrence, 2012; Olive, 2009) .
Pharmacological manipulations of mGluRs may be obtained through ligands acting at the orthosteric site or allosteric sites of the receptor. Allosteric modulators of mGluRs provide novel opportunities for drug discovery, potentially leading to drugs characterized by more specific effects and fewer side effects than other drugs affecting glutamate transmission (Conn et al., 2009) . As regards to the mGluRs of Group I, mGluR5 negative allosteric modulators (NAMs) reduce drug intake, drug-associated reward and reinforcement, and relapse-related behaviors (Besheer et al., 2008; Mihov and Hasler, 2016; Olive, 2009; Olive, 2010) .
GET 73 (N-[4-(trifluoromethyl) benzyl]-4-methoxybutyramide; PubChem SID: 329974174) is a novel chemical entity that seems to partially act like a mGluR5 antagonist or NAM (Beggiato et al., 2013; Ferraro et al., 2011) . In selectively bred Sardinian alcohol-preferring (sP) rats, a validated rodent model of AUD (Bell et al., 2012; Colombo et al., 2006) , GET 73 reduces voluntary alcohol intake, alcohol deprivation effect, and anxiety-like behaviors (Loche et al., 2012) . Furthermore, GET 73 shows a neuroprotective role against alcohol-induced neurotoxicity in primary cultures of rat hippocampal neurons (Tomasini et al., 2016) . In addition, previous in vitro and in vivo work conducted in different preclinical experimental models demonstrated the safety of GET 73 in the central nervous system, cardiovascular, respiratory, and immune systems. Together, these results indicate that GET 73 may represent a potentially safe and effective novel pharmacotherapy for AUD that should be investigated further.
The safety, tolerability, and pharmacokinetics (PK) of GET 73 in humans was recently investigated in a double-blind, placebocontrolled first-in-man study conducted by single doses up to 600 mg and repeated ascending doses up to 450 mg twice a day (Haass-Koffler et al., 2017a,b) . All adverse events (AEs) were mild to moderate in severity. Maximum plasma drug concentrations occurred between 0.5-2.05 h after administration for both single and repeated doses. The PK parameters of 4-oxo-4-{[4-triflouromethyl)benzyl]amino}butanoic acid, (MET2) the main metabolite of GET 73, were consistent with those of the parent drug. The safety, tolerability, and PK data of GET 73 in humans (Haass-Koffler et al., 2017a,b) led to further development of GET 73 as a potential treatment for AUD.
In the current study, we assessed the PK profile of GET 73 and its main metabolite MET 2, when GET 73 is co-administered with alcohol. It is critical to assess the safety and tolerability of GET 73 when co-administered with alcohol, given the potentially serious consequences of drug-alcohol interactions (Haass-Koffler et al., 2017a,b) , an approach consistent with recent guidelines from the Food and Drug Administration (Food and Drug Administration, 2015) and with the European guidelines (European Medicines Agency, EMA/ CHMP/EWP/20097/2008 Guidelines, 2010) on the development of medicinal products for the treatment of alcohol dependence.
The primary objective of this study was to provide information on the safety and tolerability of GET 73 in rats and humans when co-administered with alcohol. Additional aims were to determine the effect of alcohol on the bioavailability of GET 73 and of its major metabolite MET 2 in healthy volunteers.
Methods and materials

Rat study
The study was conducted at the Neuroscience Institute, National Research Council of Italy, Section Cagliari, Italy. Experiments were carried out in strict accordance with the European Communities Council Directive (86/609/EEC) and the Guidelines released by the Italian Ministry of Health (D.L. 116/92) and (D.L. 111/94-B). A formal approval to conduct the experiments described was obtained by the local Ethics Committee. Two independent experiments were conducted, each one employing a separate set of rats.
Experiment 1: locomotor activity
Male, adult Sprague-Dawley rats (Supplementary Material, Text S1) were divided into six groups (n=12 each), matched for body weight and treated with an empty stomach with the described six drug combinations (Table 1) . GET 73 and alcohol were administered intragastrically (i.g.). GET 73 was administered 30 min before alcohol. Five minutes after alcohol administration, rats were exposed to the motility cage for 60 min.
Experiment 2: sedation/hypnosis
Male, adult Sprague-Dawley rats were divided into three groups (n=12 each), GET 73 was administered i.g., alcohol was administered intraperitoneally (i.p.) 30 min after GET 73. Groups were matched for body weight, and treated with an empty stomach with three drug combinations (Table 1) .
Statistical analysis
For Experiment 1, the measured variable was the total number of motility counts (photocell breaks; measure of horizontal, locomotor activity) recorded automatically by the apparatus over the 60-minute session. Data were analyzed by a two-way (GET 73 dose; alcohol dose) analysis of variance (ANOVA), followed by the Newman-Keuls test for post-hoc comparisons.
For Experiment 2, after alcohol administration, each rat was placed on its back once every 30 s until the animal was unable to right itself within 60 s. The time lapse between alcohol administration and beginning of inability of the rat to right itself was measured as onset of loss of righting reflex (LORR). Subsequently, each rat was left undisturbed on its back until it spontaneously regained its righting reflex. Onset and duration of LORR were used as indexes of alcohol intoxication. They were expressed in minutes, respectively, and analyzed by separate one-way ANOVAs. 
Human study
Design, medication and alcohol dosing selection
This was an open-label, counterbalanced, randomised, crossover study conducted in healthy male volunteers conducted in (Haass-Koffler et al., 2017a,b) . Repeated administration of GET 73 at extremely short intervals to achieve a steady state would not be safe, neither would this be feasible for clinical use. Behavioral data, however, suggest that GET 73 may last longer and support an eight-hour dosing interval (Loche et al., 2012; Ottani et al., 2007; Tacchi et al., 2008) . Simultaneous administration of alcohol and GET 73 at eight-hour intervals allowed investigations of drug-alcohol pharmacodynamic (PD) effects, drug/ metabolite accumulation and change in PK. All doses of GET 73 were administered after overnight fasting, with 240 mL of water, and within 15 min of receiving the soda±alcohol (12 g). GET 73 doses and the alcohol administration rationale are further described in Supplementary Material, Text S3 and additional information on experimental procedures is provided in Supplementary Material, Text S4. The assessment schedule is in Supplementary Material, Table S1 and the timing of medication administration, PK blood samples, electrocardiogram (ECG), and vital signs measurements are in Supplementary Material, Tables S2 and S3.
Experiment 3 (300 mg GET 73 once in the absence/presence of alcohol)
Fourteen healthy male volunteers were enrolled in the study to receive a single 300 mg dose of GET 73 either with soda with no alcohol (NALC intervention) or with soda with alcohol (ALC intervention) in a randomised-counterbalanced order (Table 3) . Following completion of this period, an interim PK and safety evaluation determined the dose selected for the next experiment.
Experiment 4 (300 mg GET 73 thrice in the absence/presence of alcohol)
Eleven participants from Experiment 3 received 300 mg of GET 73 administered thrice either with NALC or ALC intervention in a randomised-counterbalanced order (Table 3) .
Statistical analysis
For GET 73 and the major metabolite MET 2, following natural logarithmic transformation, the maximum plasma concentration C max , the area under the plasma concentration-time curve from zero to last measurable concentration (AUC last ) and from zero to infinite time (AUC inf ) were subjected to analysis of variance (ANOVA) to assess for relative bioavailability comparing NALC versus ALC interventions. Participants were randomised in a counterbalanced design to control for order effects and a mixed model was used including terms for treatment received, period, and sequence fitted as fixed effects and subject within sequence fitted as a random effect.
For GET 73 and MET 2, we calculated the geometric mean (geometric coefficient of variation (CV%)) values of key PK parameters, t max was analyzed using a non-parametric Friedman X 2 -squared test (untransformed data) at the 5% level of significance to compare NALC versus ALC interventions. The CochranMantel-Haenszel test statistic and the corresponding p-value for comparing the means were calculated. Statistical analysis was performed after all participants had their follow-up visit and the study database had been locked. Data management and statistical analysis was performed by Data Magik Ltd (East Grimstead, Wiltshire, UK). All of the statistical procedures described below were performed with the package SAS (v.9.13.) and graphs were prepared using Graphpad (v.5)
Results
Rat study
Experiment 1: locomotor activity. There was a main effect of alcohol (F 1,66 =46.23, p<0.0001) , a main effect of GET 73 (F 2,66 =6.27, p<0.005) , and a GET 73×alcohol interaction (F 2,66 =5.86, p<0.005 ) on the number of motility counts. Post-hoc analyses indicated that administration of GET 73 alone (with alcohol vehicle) reduced the number of motility counts at the dose of 100 mg/kg (40% reduction compared to control rats, p<0.0005), but not at the dose of 30 mg/kg (Figure 1 ). Administration of alcohol alone (with GET 73 vehicle) resulted in a reduction of the number of motility counts (55% compared to control rats, p<0.0005) (Figure 1 ). The combination of alcohol and both doses of GET 73 did not alter the number of motility counts compared to rats treated with alcohol alone (p>0.05) ( Human study. Fourteen healthy male volunteers were randomised and 10 completed the study. Their demographic characteristics are in Table 2 and the experiments and intervention procedures are in Table 3 . The flowchart of the study is in Figure 3 .
Study population. In Experiment 3, one participant was withdrawn after dosing with NALC intervention (not available for the subsequent dosing dates), two participants were withdrawn after dosing with ALC intervention (one reported a skin rash and one was withdrawn due to a protocol violation consisting of allocation to the incorrect dose condition). In Experiment 2, one participant was withdrawn after dosing with NALC intervention (abnormal ECG). No participants were withdrawn after ALC intervention.
AEs. An overview of AEs is given in Table 4 and described in Table 5 . The incidence of AEs was low; five of the 12 participants reported a total of nine AEs, which were mild (eight) or moderate (one). There was no notable dose-related trend in the incidence of AEs and there was no notable difference between dosing in the presence or absence of alcohol. There were no serious or severe AEs.
No AE was reported by more than one individual throughout the study. In Experiment 3, one participant had sciatica after dosing with NALC intervention. All AEs were mild in severity, except for moderate urticaria reported by one participant after dosing with NALC intervention (withdrawn from the study). Three participants had the following AEs: one reported headache and nausea after dosing with NALC intervention; one had two AEs urticaria after dosing with ALC intervention. In Experiment 4, one participant had second degree atrioventricular block after dosing with NALC intervention (withdrawn from the study). Two participants had AEs that had not resolved when they completed the study (upper respiratory tract infection and a splinter). Both of these events were mild and unrelated to the study drug. Other clinical laboratory evaluations including vital signs and ECGs are in Supplementary Material, Text S5.
PK analysis for GET 73. The geometric mean and median of key PK parameters for GET 73 are in Table 6 and additional PK considerations are in Supplementary Material, Text S6.
Experiment 3: 300 mg GET 73 once. The GET 73 mean plasma concentrations after the administration of 300 mg GET 73 once, in the absence/presence of alcohol, are shown on Figure 4 . Following dosing with NALC intervention, no lag phase was apparent before the post-dose onset of quantifiable plasma concentrations of GET 73. Following an absorption phase, GET 73 concentrations were highest between 0.25-3.00 h post-dose, with evidence of multiple concentration maxima for some participants. Terminal half-life estimates ranged between 0.63-1.57 h for GET 73 following NALC intervention. Inter-subject variability in systemic exposure was high after dosing with NALC intervention; geometric CV% was 61.5% and 63.50% for C max and AUC inf .
Following dosing with ALC intervention, concentrations of GET 73 peaked between 0.25-1.50 h post-dose. Median t max values were similar to those observed for NALC intervention. A lag phase was not seen for any of the participants. Individual terminal half-life estimates were comparable to those from NALC intervention, ranging between 0.71-1.49 h post-dose. Geometric mean estimates of C max and AUC inf were higher than the corresponding values seen for NALC intervention and were reflected in the apparent bioavailability of NALC intervention relative to ALC intervention. Inter-subject variability was comparable to that seen for ALC intervention, with geometric CV% of 59.7% and 57.0% for C max and AUC inf .
For the comparison of NALC versus ALC interventions, the confidence intervals (CIs) for GET 73 AUC last , C max and AUC inf , were all below one. This suggests that, at the 10% level, the adjusted geometric means for these parameters were lower when a single 300 mg dose GET 73 was administered in the absence of alcohol than when administered in the presence of alcohol. Finally, there was no statistical difference in t max between the NALC versus ALC interventions (p>0.05).
Experiment 4: 300 mg GET 73 thrice. The GET 73 mean plasma concentration after the administration of 300 mg GET 73 thrice, in the absence/presence of alcohol, is shown in Figure 5 . Following dosing with NALC intervention, plasma concentration versus time profiles of GET 73 were consistent with three doses administered six hours apart. A lag phase was not observed for any participant, and concentration maxima occurred after each of the three doses during the dosing cycle. The inter-subject variability was high with a geometric CV% of 78.7% and 52.9% for C max and AUC inf . The reported terminal half-life estimates ranged between 1.24-1.79 h post-dose. Fourteen healthy male volunteers (10 completers) were enrolled in the study to receive a single 300 mg dose of GET 73 (N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide) (Experiment 3) and then thrice 300 mg dose of GET 73 (Experiment 4) either with soda with no alcohol (NALC) intervention or soda with alcohol (ALC) intervention in a randomised counterbalanced order. In Experiment 3, one participant was withdrawn after dosing with NALC intervention, two participants were withdrawn after dosing with ALC intervention. In Experiment 4, 11 participants received 300 mg of GET 73 thrice either with NALC or ALC interventions, in a randomised counterbalanced order, one participant was withdrawn after dosing with NALC intervention and none after ALC intervention. Following administration of ALC intervention, peak concentrations of GET 73 occurred following every dose. As with NALC intervention, no lag phase was observed. Concentrations of GET 73 were similar to those following NALC intervention. The C max and AUC inf , values were also similar. The median t max values were different for NALC and ALC interventions (2.0 h and 6.5 h). The mean t ½ values were similar to those seen for NALC intervention as was the inter-subject variability with geometric CV% of 64.8% and 67.8% for C max and AUC inf . Terminal half-life estimates ranged between 1.07-1.72 h post-dose. For the comparison of NALC versus ALC interventions, the CIs for GET 73 AUC last , C max and AUC inf , included 1. This suggests, that at the 10% level, the adjusted geometric means were similar when a 300 mg dose of GET 73 was thrice administered in the presence/absence of alcohol.
Results for the PK parameters C max , AUC last and AUC inf are in Table 7 . Finally, there was no statistical difference in the t max between the NALC versus ALC interventions (p>0.05).
PK analysis of metabolite MET 2. The key PK parameters of
MET 2 are shown in Table 7 .
Experiment 3: 300 mg GET 73 once. The MET 2 plasma concentration after the administration of 300 mg GET 73 once, in the absence/presence of alcohol, is shown in Figure 6 . Following dosing with NALC intervention, MET 2 plasma concentrations were highest between 0.5-4.00 h post-dose. A lag phase of 0.25 h was identified in two participants only. Inter-subject variability was low, with a geometric CV% of 22.2% and 16.1% for C max and AUC inf . Terminal half-life estimates ranged between 0.96-1.89 h post-dose.
Following dosing with ALC intervention, concentrations of MET 2 peaked between 0.5-3.0 h post-dose and were similar to NALC intervention. A lag phase was not apparent in any subject. The C max and AUC inf estimates for MET 2 were lower than the corresponding values seen for NALC intervention and the geometric mean value for the AUC inf ratio (ALC/NALC .3) Headache 1 (7.7) 0 0 0 1 (7.1) Sciatica 1 (7.7) 0 1 (9.1) 0 1 (7.1) Cardiac disorders 0 0 1 (9.1) 0 1 (7.1) Atrioventricular block second degree 0 0 1 (9.1) 0 1 (7.1) Gastrointestinal disorders 1 (7.7) 0 0 0 1 (7.1) Nausea 1 (7.7) 0 0 0 1 (7.1) Infections and infestations 0 0 0 1 (10.0) 1 (7.1) Upper respiratory tract infection 0 0 0 1 (10.0) 1 (7.1) Injury, poisoning and procedural complications 1 (7.7) 0 0 0 1 (7.1) Splinter 1 (7.7) 0 0 0 1 (7.1) Skin and subcutaneous tissue disorders 0 1 (7.7) 0 0 1 (7.1) Urticaria 0 1 (7.7) 0 0 1 (7.1) ALC: soda with alcohol; GET 73: N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide; NALC: soda with no alcohol. Experiment 4: 300 mg MET 2 thrice. The MET 2 plasma concentration after the administration of 300 mg GET 73 thrice, in the absence/presence of alcohol, is shown in Figure 7 . Following dosing with NALC intervention, plasma concentrations of MET 2 peaked following each dose of GET 73 within the dose cycle. A lag phase was not seen for any of the subjects. The inter-subject variability was low with a geometric CV% of 21.8% and 21.7% for C max and AUC inf , respectively. Terminal half-life estimates ranged between 1.22-2.54 h. Following dosing with intervention ALC, MET 2 concentration maxima were apparent following each dose of GET 73, with no lag phase seen for any participants. While mean estimates of C max intervention ALC were similar to those seen for NALC intervention; the geometric mean value for the AUC inf ratio (ALC/NALC intervention) was 0.96, which was closer to unity than that reported for NALC intervention. The t ½ and t max values were similar to those seen for NALC intervention and the intersubject variability was low with a geometric CV% of 27.6% and 22.7% for C max and AUC inf . Individual terminal half-life estimates range between 1.18-2.68 h. The results of the statistical analyses for MET 2 for the PK parameters C max , AUC last and AUC inf , are shown in Table 7 , and results for the bioavailability analysis of MET 2 are shown in Table 8 .
In Experiment 3, for the comparison of NALC versus ALC interventions, the CIs for MET 2 C max , AUC last and AUC inf were all above one. This suggests, that at the 10% level, the adjusted geometric means for these parameters were higher when a single 300 mg dose of GET 73 was administered in the absence of alcohol than when administered in the presence of alcohol.
In Experiment 4, for the comparison of NALC versus ALC interventions, the CIs for MET 2AUC last and AUC inf included 1. This suggests that, at the 10% level, the adjusted geometric means for these parameters were similar when a 300 mg thrice a day dose of GET 73 was administered in the presence or absence of alcohol. For MET 2 C max , the CI was entirely above one, suggesting that, at the 10% level, the adjusted geometric mean C max was higher when a 300 mg thrice a day dose of GET 73 was administered in the absence of alcohol than when administered in the presence of alcohol.
For MET 2, t max values were not significantly different in NALC versus ALC interventions (p>0.05). For the statistical analysis of relative bioavailability, the residual plots, the normal probability plots, and the plots of the residuals against the predicted values (i.e. the distributional assumptions underlying the statistical analysis, the assumptions of normality and homogeneity of variance) were satisfied.
Discussion
This study was the first to investigate and provide evidence of the safety of the administration of GET 73 with alcohol both in rats and humans. In humans, we also measured the bioavailability of GET 73 and of its major metabolite MET 2 after GET 73 was administered with alcohol. Based on the PK of GET 73 and MET 2, there were no significant differences in bioavailability between administering 300 mg GET 73 either once or thrice in the presence or absence of alcohol. In rats, when given a dose equivalent to the human dose alone, GET 73 did not alter spontaneous locomotor activity (parameter highly sensitive to the rat well-being), indicating that this dose of GET 73 was per se devoid of any motor-incoordinating, ataxic, and sedative effects. Second, neither 30 mg/kg nor 100 mg/kg GET 73 altered the intoxicating effects of alcohol. The doses of alcohol used in the rat experiments were selected to produce different degrees of alcohol intoxication, varying from hypolocomotion to sedation/hypnosis. The results of these two rat experiments suggest that GET 73 did not potentiate alcoholinduced intoxication. These results are relevant from a translational standpoint given that we tested doses of GET 73 that are equivalent to the doses employed in humans and in the range of those found to be pharmacologically effective in reducing alcohol drinking and anxiety-related behaviors in a rat model of AUD (Loche et al., 2012) . The lack of any GET 73-induced potentiation of alcohol intoxication observed in these two rat experiments complements the lack of notable differences in AEs in humans receiving GET 73 in the presence/absence of alcohol.
Our results in humans hold clinical importance because GET 73 was well-tolerated when administered with alcohol with no severe or serious AEs. The overall incidence of AEs was low, and there was no notable difference between dose levels. Furthermore, for the few AEs observed, it is not possible to fully determine whether these AEs were attributed to the medication since the study did not included a placebo-controlled arm.
After a single oral dose of 300 mg GET 73 (absence of alcohol), the geometric mean C max and AUC last and median t max values were consistent with those reported in the previous first-in-man study at the 300 mg dose level which confirms the reproducibility of the GET 73 PK profile in healthy males (Haass-Koffler et al., 2017a,b) . When GET 73 was administered with alcohol the geometric means of C max and AUC inf were higher, with a two-fold and 1.5-fold increase, compared to GET 73 administration without alcohol. In contrast, both t max and t ½ appeared to be largely unchanged by the presence of alcohol. For MET 2, there appeared to be a decrease in C max (32%) and AUC inf (16%) in the presence of alcohol. However, t max and t ½ of MET 2 were similar in the absence and presence of alcohol. These data indicate that following a single 300 mg oral dose in the presence of alcohol, systemic exposure to GET 73 increased; this increase might be due, in part, to a reduction in the extent of metabolic conversion to MET 2.
The trend towards greater systemic exposure in the presence of alcohol was not observed following repeat (300 mg thrice) doses of GET 73. The mean C max and AUC inf values of GET 73 were similar in the absence and presence of alcohol. The median t max values were different for NALC and ALC interventions (2.0 h and 6.5 h); however, the range of individual t max estimates was similar for both treatments.
We observed a decrease in C max for MET 2 (25%) in the presence of alcohol, although the extent of total systemic exposure was similar. The occurrence of t max was variable following each dose. The terminal half-life of MET 2 was similar following multiple doses of GET 73 in the presence/absence of alcohol. Total systemic exposure to GET 73 following the thrice a day dosing of 300 mg GET 73 was approximately three-fold greater than that observed following a single 300 mg dose (NALC intervention) and was therefore broadly proportional to the total dose administered. Observed concentration maxima were, however, comparable between NALC intervention with the 300 mg once dose and 300 mg thrice dose, suggesting little or no accumulation of GET 73 over the thrice dosing cycle. Corresponding treatment comparisons in the presence of alcohol, the ALC intervention also suggested proportionality of total systemic exposure to total dose of GET 73 administered. The metabolite MET 2 also exhibited a proportional relationship between GET 73 dose and systemic exposure (regardless of alcohol status), once again with little evidence of accumulation following thrice a day dosing. This study provides preliminary evidence of no accumulation of GET 73 or its metabolite with the thrice 300 mg dosing both in the absence/presence of alcohol. This study should be seen in light of both its strengths and limitations. Strengths include: (a) this study was a direct rat-tohuman translation work on the drug-alcohol interaction of a putative compound for AUD; (b) we collected human PK information not only on the parent drug, but also on its main metabolite MET 2; and (c) GET 73 was tested both as single and as multiple dosing administrations. Limitations include that: (a) the study was not a fully factorial design (open-label, no GET 73-matched placebo); (b) only male rats and male humans were included; and (c) the amount of alcohol co-administered was relatively low in humans. Nonetheless, given that this was the first study of its kind, it was prudent to start with low alcohol doses to assess safety as related to drug-alcohol interactions. Also, there is a general consensus on the need for women to be included in research trials, in order to ensure a correct evaluation of gender differences during drug development. However, no sufficient genotoxicity data were available at the time of the study; in addition the small sample size did not allow a reliable gender difference evaluation. Future studies will need to look as the safety and PK profile of GET 73 when administered with higher doses of alcohol. Finally, a recent study showed a decrease in mGluR5 receptor binding in smokers and ex-smokers (Akkus et al., 2013) ; given the high incidence of alcohol and smoking comorbidity, future studies could investigate the role of GET 73 in tobacco use.
In conclusion, this study provides evidence on the safety and tolerability of GET 73 during an acute alcohol challenge experimental procedure and further supports future research towards investigating GET 73 as a novel pharmaceutical to treat patients with AUD.
